The financials
Medline Inc. by the numbers
Medline Inc. (MDLN) reported revenue of $7.68B in Q2 2026 (quarter ended June 27, 2026), up 16% from the same quarter a year earlier. That came with a gross margin of 29% and net income of $139M (1.8% of revenue). For the full year FY2025, revenue was $28.4B (+11% year on year) and net income $1.16B. Its largest product in 2026-Q2 was Acute Care at $5.41B, 73% of the disclosed total, just ahead of Non Acute Care at 24%.
| Income statement | Q2 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $7.68B | $6.64B | +16% |
| Gross profit | $2.21B | $1.82B | +21% |
| Operating income | $395M | $571M | −31% |
| Net income | $139M | $319M | −56% |
| Diluted EPS | $0.07 | n/a | n/a |
| Product | Revenue | Share |
|---|---|---|
| Acute Care | $5.41B | 73% |
| Non Acute Care | $1.75B | 24% |
| Laboratory And Diagnostics | $248M | 3.4% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $7.40B (+3.5%)
Segment Latestquarter on quarteryear on year
- Acute Care$5.41B$5.41BQoQ +5.5%year on year +15%+5.5%+15%
- Non Acute Care$1.75B$1.75BQoQ +0.75%year on year +3.7%+0.75%+3.7%
- Laboratory And Diagnostics$248.0M$248.0MQoQ -15%year on year +12%-15%+12%
Medical Instruments & Supplies
The closest names by size in the same industry